Q2 2026 Verastem Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €5.14 (+2.19%)

Transcript 8-K10-Q

Key Points

Positve

Verastem Inc (VSTM) reported strong Q2 2026 net product revenues of $25.1 million, reflecting a meaningful rebound and continued execution of its commercial strategy for the LGSOC franchise.
The company strengthened its balance sheet with a non-dilutive royalty financing agreement with Oberlin Capital for up to $75 million, plus a $15 million milestone payment from Secure Bio, providing capital to fund operations into the second half of 2027.
Commercial execution is improving, with growing physician confidence, increased new patient starts, earlier lines of therapy adoption, and higher refill consistency, indicating patients are staying on treatment longer.
The VS 7,375 program is advancing rapidly, with completed enrollment in dose expansion cohorts, FDA fast track designation for non-small cell lung cancer, and initiation of all three phase 2 registration-directed studies.
Preliminary clinical data for VS 7,375 shows encouraging anti-tumor activity and a favorable tolerability profile, with a notable case of a patient achieving a >65% tumor shrinkage within six weeks, supporting its potential as a best-in-class KRAS G12D inhibitor.
The company expects the LGSOC business to become self-sustaining by the end of 2026, with commercial revenue supporting both the commercial organization and the development franchise.

Negative

Verastem Inc (VSTM) continues to report significant net losses, with a non-GAAP adjusted net loss of $30.6 million in Q2 2026, though improved from the prior year.
The company faces intense competition in the KRAS G12D space, with other inhibitors like PANRAS and RevMed's G12D data potentially impacting the perceived differentiation of VS 7,375.
There is uncertainty regarding the translatability of clinical data from the Gen Fleet China study to the US population, given known differences in PK behavior and disease management.
The commercial launch of the COPA franchise still faces challenges, including a learning curve for physicians in managing adverse events and setting patient expectations, which could impact adherence and long-term adoption.
The company's ability to achieve accelerated approval for VS 7,375 is not guaranteed, as the FDA has not provided explicit guidance on the required bar, and the company must rely on historical benchmarks like a 30% ORR and 6-month durability.
The company's future growth depends on successful partnership discussions, particularly for PRMT5, and any delays or failures in these negotiations could limit the potential acceleration of its pipeline programs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VSTM.OQ - Verastem Inc
Q2 2026 Verastem Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Veraem oncology second quarter 2026 earnings conference call.

My name is Olivia and I'll be a call operator today.

Please note this event is being recorded.

All participants will be in a listen-only mode.

After today's presentation, there will be an opportunity to ask questions.

I will now send the call over to Julisa Vienna, senior Vice President corporate communications, investor relations, and patient advocacy at Verisimm Oncology.

Please go ahead.

Thank you, operator.

Welcome, everyone, and thank you for joining us today to discuss Veris second quarter 2026 financial results and recent business updates.

This afternoon we issued a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.